Business Context and Reporting Period
This Form 8-K filing by Cytomx Therapeutics, Inc. reports on events occurring on May 12, 2017, and May 15, 2017. The filing addresses significant changes in executive leadership, specifically the departure of the Chief Financial Officer (CFO) and the appointment of a successor.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements and equity grants related to the leadership transition.
Material Changes
- Departure of CFO: Robert C. Goeltz II resigned as Chief Financial Officer, effective May 15, 2017, to pursue new opportunities.
- Appointment of New CFO: Debanjan Ray was promoted to Chief Financial Officer, Principal Financial and Accounting Officer, and Head of Corporate Development, effective May 15, 2017.
- Compensation Changes:
- Outgoing CFO: Separation agreement includes 12 months of base salary, up to 12 months of healthcare reimbursement, a pro-rated 2017 target bonus, and an extension of option exercise periods to January 31, 2019.
- Incoming CFO: Annual base salary increased to $375,000 with a discretionary annual bonus target of 40% of base salary.
- Equity Grant: Mr. Ray received an option to purchase 30,000 shares of common stock at an exercise price of $14.62, vesting monthly over 48 months.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The primary contingency noted is the execution of the Separation Agreement with the departing CFO, the full text of which is to be filed as an exhibit to the subsequent Form 10-Q.
Investor Verification Checklist
- Verify the full terms of the Separation Agreement with Robert C. Goeltz II in the upcoming Form 10-Q.
- Confirm the vesting schedule and performance conditions for Debanjan Ray's new equity grant.
- Monitor the transition of financial reporting responsibilities to ensure continuity.
- Review the impact of the leadership change on the company's corporate development strategy.